In the last few years, immunotherapy has become part of everyday clinical practice for the treatment of many solid tumors including metastatic non-small-cell lung cancer. These drugs, however, can yield a specific toxicity profile that consists of immune-related adverse events (irAEs). Hepatotoxicity is one of irAEs and occurs in about 1-3% of cases and may be manifested by the presence of increate levels of liver enzymes (aspartate aminotransferase, alanine aminotransferase) and/or biliary stasis evidence; in these cases, a differential diagnosis with other hepatic diseases must be considered. We present the case of a 73-year-old man who presented with an alteration in liver function during treatment with pembrolizumab (anti-programmed death 1 monoclonal antibody) for a stage IV nonsquamous non-small-cell lung cancer, which was initially mistaken for drug-induced irAEs hepatic toxicity.

Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: A case report / Osman, G. A.; Marra, A.; Iacono, D.; Giannelli, V.; Ricciardi, S.; Remotti, D.; Vecchione, A.; Ricci, A.; Palange, P.; Migliorino, M. R.. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 30:7(2019), pp. 757-761. [10.1097/CAD.0000000000000764]

Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: A case report

Remotti D.;Vecchione A.;Ricci A.;
2019

Abstract

In the last few years, immunotherapy has become part of everyday clinical practice for the treatment of many solid tumors including metastatic non-small-cell lung cancer. These drugs, however, can yield a specific toxicity profile that consists of immune-related adverse events (irAEs). Hepatotoxicity is one of irAEs and occurs in about 1-3% of cases and may be manifested by the presence of increate levels of liver enzymes (aspartate aminotransferase, alanine aminotransferase) and/or biliary stasis evidence; in these cases, a differential diagnosis with other hepatic diseases must be considered. We present the case of a 73-year-old man who presented with an alteration in liver function during treatment with pembrolizumab (anti-programmed death 1 monoclonal antibody) for a stage IV nonsquamous non-small-cell lung cancer, which was initially mistaken for drug-induced irAEs hepatic toxicity.
2019
immuno-related toxicity; immunotherapy; non-small-cell lung cancer; pembrolizumab
01 Pubblicazione su rivista::01a Articolo in rivista
Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: A case report / Osman, G. A.; Marra, A.; Iacono, D.; Giannelli, V.; Ricciardi, S.; Remotti, D.; Vecchione, A.; Ricci, A.; Palange, P.; Migliorino, M. R.. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 30:7(2019), pp. 757-761. [10.1097/CAD.0000000000000764]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1390844
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact